Eloralintide: Lilly's Next Weight-Loss Peptide After Retatrutide, Explained

Use code PEPHUB at Petratide Science, True Amino Labs, Blue Ridge Peptides, Zen Aminos!

If you've read the retatrutide guide, you know Lilly's pipeline doesn't stop at triple agonists. There's another compound moving through their obesity program that works on a completely different pathway, and the early data is genuinely impressive: eloralintide, an amylin receptor agonist that just posted 20%+ weight loss in a Phase 2 trial. Let's break down what it is, how it's different from everything else in this space, and where the research actually stands.

What Is Eloralintide?

Eloralintide (research code LY3841136) is a synthetic peptide developed by Eli Lilly. It belongs to a completely different drug class than retatrutide, tirzepatide, or semaglutide — instead of targeting GLP-1, GIP, or glucagon receptors, it's a selective amylin receptor agonist.

Amylin is a hormone the pancreas already makes alongside insulin. It plays a role in appetite regulation and how full you feel after eating — a different mechanism entirely from the GLP-1 family, which is exactly why researchers are excited about it. It's not a replacement for GLP-1 drugs; it's a different lever on the same overall problem, and Lilly is studying it both on its own and stacked with tirzepatide.

• Chemical Classification: Amylin receptor agonist (AMY1R-selective)
• Administration: Subcutaneous injection, once weekly
• Development Status: Phase 3 clinical trials, enrollment underway as of 2026
• Developer: Eli Lilly and Company

The "Selective" Part Is the Whole Point

Amylin analogs aren't new — Novo Nordisk's cagrilintide (the amylin half of CagriSema) has been the one to beat in this class. What makes eloralintide different is receptor selectivity.

Amylin can activate a few related receptors, including one called the calcitonin receptor (CTR). Older, non-selective amylin drugs light up CTR along with the amylin receptors, and CTR activation is one of the things researchers link to nausea and food-aversion side effects. Eloralintide was specifically engineered to hit the amylin 1 receptor (AMY1R) far more selectively — Lilly's own preclinical data shows it activating AMY1R roughly 12 times more potently than CTR.

In animal studies, that selectivity showed up as a real difference: eloralintide caused significantly less "conditioned taste avoidance" (a lab proxy for nausea-driven food aversion) in rats compared to cagrilintide. The bet Lilly is making is that a more targeted molecule means comparable or better weight loss with an easier side-effect profile — and so far, the human data backs that up.

What Does the Research Actually Show?

Phase 1: Proof of Concept

Eloralintide's first human data came from two Phase 1 trials. A single-ascending-dose study in healthy participants tested doses from 0.04 to 12 mg and was generally well tolerated. A separate 12-week multiple-ascending-dose study in 100 participants with obesity or overweight (average BMI 32.6) found:

• Weight loss up to 11.3% at 12 weeks in the highest-response cohort
• As little as 2.6% in the lowest-dose cohort
• Adverse events were mostly mild — of the participants who reported side effects, the large majority were mild in severity, with a small number of moderate GI events (including one case of vomiting)

That's a strong early signal for just 12 weeks of dosing.

Phase 2: The Data That Got Everyone's Attention

The real headline came from a 48-week Phase 2 trial of 263 adults with obesity or overweight (with at least one weight-related health complication, no type 2 diabetes), published in The Lancet and presented at ObesityWeek in November 2025.

Every treatment arm beat placebo by a wide margin, and the trial hit its primary endpoint across the board. Tolerability was described as favorable — mild-to-moderate GI symptoms were the most common issue, and incidence was similar to placebo in the lower-dose groups.

For comparison, Novo Nordisk's CagriSema (cagrilintide + semaglutide combined) has posted 20–23% weight loss at 68 weeks, and their newer amycretin candidate reported around 22% at 36 weeks. Eloralintide is putting up comparable numbers as a single agent, at 48 weeks, in a class Lilly entered later than its competitors — which is part of why analysts have taken notice.

What's Next: Phase 3

Based on those Phase 2 results, Lilly moved straight into Phase 3. Several large studies are already recruiting:

• ENLIGHTEN-1 — obesity/overweight without type 2 diabetes, started February 2026, estimated completion in 2028
• ENLIGHTEN-2 — obesity/overweight with type 2 diabetes, started December 2025, estimated completion in 2028
• ENLIGHTEN-3 — obesity/overweight with moderate-to-severe obstructive sleep apnea

Lilly is also running a separate study combining eloralintide with tirzepatide, testing whether stacking an amylin agonist on top of the GLP-1/GIP combination pushes results even further — a strategy that would mirror what Novo Nordisk has already done pairing cagrilintide with semaglutide.

Where This Sits in the Bigger Picture

The amylin space has gotten crowded fast. Novo Nordisk, AbbVie, Roche, and Zealand Pharma all have amylin-targeting candidates in some stage of development, and industry analysts increasingly view amylin agonists — alone or paired with a GLP-1/GIP drug — as the next real leap in this category, rather than another marginal iteration.

Eloralintide's pitch is specificity: comparable efficacy to the non-selective options, with a tolerability edge from hitting a narrower target. Whether that edge holds up at scale, and whether the combination studies with tirzepatide show a meaningful boost over either compound alone, are the two questions worth watching as Phase 3 data starts to roll in.

Honest Gaps: What We Don't Know Yet

• No long-term data. 48 weeks is the longest published dataset so far. Durability, weight regain after stopping, and rare long-term effects are all unknowns.
• Limited population diversity so far. Trial populations to date have been relatively narrow; broader Phase 3 enrollment (already underway) should fill this in.
• Combination data is still pending. The eloralintide + tirzepatide studies haven't reported results yet — that's arguably the more commercially important question than eloralintide alone.
• Regulatory path and timeline are genuinely unclear. This compound just started Phase 3. Any future filing or approval decision is realistically years out and depends entirely on how those trials read out.

A Note on Availability

Because eloralintide only just entered Phase 3 and the Phase 2 data was published in late 2025, it's genuinely new to the research space — availability through peptide vendors varies and may be limited compared to well-established compounds like retatrutide or tirzepatide. If you're specifically looking for it, check current listings with your usual source rather than assuming it's stocked everywhere; this guide will be updated with vendor-specific notes once availability is more consistent across the vendors linked on this site.

Frequently Asked Questions

What is eloralintide?

Eloralintide (LY3841136) is an investigational, once-weekly injectable peptide developed by Eli Lilly. It's a selective amylin receptor agonist being studied for weight loss in adults with obesity or overweight, with and without type 2 diabetes.

How is eloralintide different from retatrutide or tirzepatide?

Retatrutide and tirzepatide are GLP-1-family drugs that target GLP-1, GIP, and/or glucagon receptors. Eloralintide works on an entirely different pathway — the amylin receptor — and is engineered to be more selective for that receptor than older amylin drugs, which may mean fewer nausea-related side effects.

How much weight loss has eloralintide shown in trials?

In a 48-week Phase 2 trial, weight loss ranged from 9.5% to 20.1% across dose groups, compared to 0.4% with placebo. All doses met the trial's primary endpoint.

Is eloralintide the same as cagrilintide?

No, but they're in the same drug class (amylin receptor agonists). Cagrilintide is Novo Nordisk's compound, and it's non-selective — it also activates the calcitonin receptor. Eloralintide is engineered to be more selective for the amylin receptor specifically, which early animal and human data suggests may improve tolerability.

Is eloralintide approved for use?

No. Eloralintide is investigational and currently in Phase 3 trials. Any future regulatory filing or approval will depend entirely on the outcome of those trials, which are expected to run into 2028.

Can eloralintide be combined with tirzepatide?

Lilly is actively studying this combination in a separate trial, but results haven't been published yet. It's a reasonable research question given how amylin/GLP-1 combinations have performed for competitors, but there's no published human data on the combination as of this guide.

Disclaimer: All content on ResearchPepHub is for educational and research purposes only. Eloralintide is not intended for human consumption. Always consult a qualified professional before beginning any research protocol. These statements have not been evaluated by the FDA. I'm an affiliate for vendors linked and may earn commissions from purchases.

Tags: eloralintide, LY3841136, amylin, Eli Lilly, weight loss peptide, obesity research, cagrilintide comparison